Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 77,862
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12590110 | Amorphous (a-polymorphic) psilocybin | 🖼🧊📄§ | 2026-03-31 | 2044-07-05 | 0 | 31 |
| 12590293 | Method for obtaining a platelet derived secretome and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2042-08-24 | 0 | 31 |
| 12590305 | Complement component C5 iRNA compositions and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2043-12-05 | 0 | 31 |
| 12590311 | Methods and compositions for the treatment of cancer | 🖼🧊📄§ | 2026-03-31 | 2040-06-18 | 0 | 31 |
| 12590312 | NR4A super-repressors and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-05-21 | 0 | 31 |
| 12590321 | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof | 🖼🧊📄§ | 2026-03-31 | 2040-03-18 | 0 | 31 |
| 12590333 | N-Myc-interactor protein as a marker for chronic lung disease and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2043-11-30 | 0 | 31 |
| 12590057 | Crystalline complexes | 🖼🧊📄§ | 2026-03-31 | 2041-04-08 | 0 | 31 |
| 12590068 | Crystalline salts of a plasma kallikrein inhibitor | 🖼🧊📄§ | 2026-03-31 | 2045-08-28 | 0 | 31 |
| 12590094 | Compounds for the treatment of neurodegenerative and metabolic disorders | 🖼🧊📄§ | 2026-03-31 | 2040-05-14 | 0 | 31 |
| 12590111 | Flavonoid derivative for treating dental caries | 🖼🧊📄§ | 2026-03-31 | 2040-08-20 | 0 | 31 |
| 12590121 | Peptide compound with repetitive sequences | 🖼🧊📄§ | 2026-03-31 | 2041-08-13 | 0 | 31 |
| 12590126 | Compounds for selective disruption of protein-protein interactions | 🖼🧊📄§ | 2026-03-31 | 2043-08-24 | 0 | 31 |
| 12590129 | Liver-specific regulatory nucleic acid sequences | 🖼🧊📄§ | 2026-03-31 | 2039-11-19 | 0 | 31 |
| 12590130 | Bipartite molecules and uses thereof in treating diseases associated with abnormal protein aggregates | 🖼🧊📄§ | 2026-03-31 | 2040-11-27 | 0 | 31 |
| 12590133 | IL-13/IL-4 superkines: immune cell targeting constructs and methods of use thereof | 🖼🧊📄§ | 2026-03-31 | 2039-06-03 | 0 | 31 |
| 12590134 | GLP-1 agonist polypeptide compound and salt thereof, synthesis method therefor and use thereof | 🖼🧊📄§ | 2026-03-31 | 2042-08-17 | 0 | 31 |
| 12590135 | Stabilized extracellular domain of CD19 | 🖼🧊📄§ | 2026-03-31 | 2040-02-12 | 0 | 31 |
| 12590137 | Meditope-enabled T cells | 🖼🧊📄§ | 2026-03-31 | 2038-12-31 | 0 | 31 |
| 12590138 | Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD64 | 🖼🧊📄§ | 2026-03-31 | 2043-09-26 | 0 | 31 |
| 12590144 | Cardiac troponin I specific antibody, kit and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2043-10-02 | 0 | 31 |
| 12590145 | Bi-specific chimeric antigen receptor | 🖼🧊📄§ | 2026-03-31 | 2041-05-18 | 0 | 31 |
| 12590147 | TRPV1 epitopes and antibodies | 🖼🧊📄§ | 2026-03-31 | 2040-12-10 | 0 | 31 |
| 12590152 | CD3-specific binding molecules | 🖼🧊📄§ | 2026-03-31 | 2040-01-30 | 0 | 31 |
| 12590146 | CLDN18.2-targeting antibody, preparation method therefor, and use thereof | 🖼🧊📄§ | 2026-03-31 | 2040-09-29 | 0 | 31 |
| 12590148 | Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy | 🖼🧊📄§ | 2026-03-31 | 2039-11-22 | 0 | 31 |
| 12590150 | Antibody against Nectin-4 and application thereof | 🖼🧊📄§ | 2026-03-31 | 2041-04-21 | 0 | 31 |
| 12590154 | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling | 🖼🧊📄§ | 2026-03-31 | 2045-04-29 | 0 | 31 |
| 12590159 | Compositions targeting epidermal growth factor receptor and methods for making and using the same | 🖼🧊📄§ | 2026-03-31 | 2045-02-25 | 0 | 31 |
| 12590156 | Fusion antibody for presenting antigen-derived T cell antigen epitope or peptide containing same on cell surface, and composition comprising same | 🖼🧊📄§ | 2026-03-31 | 2041-02-05 | 0 | 31 |
| 12590158 | Anti-trka antibody or antigen-binding fragment thereof, preparation method thereof, and application thereof | 🖼🧊📄§ | 2026-03-31 | 2042-02-23 | 0 | 31 |
| 12590161 | Anti-C-MPL antibody and use thereof | 🖼🧊📄§ | 2026-03-31 | 2041-11-09 | 0 | 31 |
| 12590160 | Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function | 🖼🧊📄§ | 2026-03-31 | 2042-07-25 | 0 | 31 |
| 12590166 | CD20 binding molecules and uses thereof | 🖼🧊📄§ | 2026-03-31 | 2041-07-16 | 0 | 31 |
| 12590163 | Agonistic anti-IL-2R antibodies and methods of use | 🖼🧊📄§ | 2026-03-31 | 2043-08-29 | 0 | 31 |
| 12590167 | Combination therapies against cancer targeting CD38 and TGF-β | 🖼🧊📄§ | 2026-03-31 | 2039-07-10 | 0 | 31 |
| 12590187 | Polymer composite capable of being quickly dissolved or dispersed in aqueous solvent and preparation method and application thereof | 🖼🧊📄§ | 2026-03-31 | 2041-08-19 | 0 | 31 |
| 12589080 | Enhanced two-stage microparticle-based localized therapeutic delivery system | 🖼🧊📄§ | 2026-03-31 | 2042-06-01 | 0 | 31 |
| 12589082 | Compositions comprising thymoquinone and additional biologically active compounds | 🖼🧊📄§ | 2026-03-31 | 2040-01-27 | 0 | 31 |
| 12589079 | Gene delivery system and application thereof in preparation of drugs for treatment of tumors | 🖼🧊📄§ | 2026-03-31 | 2045-05-10 | 0 | 31 |
| 12589086 | Compositions and methods for the treatment of primary biliary cholangitis | 🖼🧊📄§ | 2026-03-31 | 2041-08-25 | 0 | 31 |
| 12589087 | Enantiomer selective action on neurotransmission | 🖼🧊📄§ | 2026-03-31 | 2042-04-01 | 0 | 31 |
| 12589083 | Abuse-deterrent dosage forms containing esketamine | 🖼🧊📄§ | 2026-03-31 | 2041-11-10 | 0 | 31 |
| 12589090 | Compounds and methods for the treatment of degenerative disorders | 🖼🧊📄§ | 2026-03-31 | 2040-01-21 | 0 | 31 |
| 12589089 | PTGDR-1 and/or PTGDR-2 antagonists for preventing and/or treating systemic lupus erythematosus | 🖼🧊📄§ | 2026-03-31 | 2044-03-12 | 0 | 31 |
| 12589091 | Topical formulation comprising sirolimus | 🖼🧊📄§ | 2026-03-31 | 2042-02-09 | 0 | 31 |
| 12589093 | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders | 🖼🧊📄§ | 2026-03-31 | 2040-04-08 | 0 | 31 |
| 12589097 | Apilimod compositions and methods of use | 🖼🧊📄§ | 2026-03-31 | 2043-08-03 | 0 | 31 |
| 12589095 | Unit dosage form for transmucosal drug delivery of an active pharmaceutical ingredient | 🖼🧊📄§ | 2026-03-31 | 2040-05-29 | 0 | 31 |
| 12589099 | Alpha-1062 for treating traumatic brain injury | 🖼🧊📄§ | 2026-03-31 | 2042-11-25 | 0 | 31 |